Treatment Action Group launches the 2023 Tuberculosis Diagnostics Pipeline Report.

Médecins Sans Frontières issues a report offering case studies of two critical TB tools, GeneXpert and delamanid, and outlining actions that the corporations making them need to take to unlock access to these tools.

An international survey seeks to determine the most important outcomes to measure in Phase 3 trials of pulmonary TB treatment.

The TB REACH Wave 11 call for proposals is focused on innovative approaches to integrate TB service delivery with lung health at the primary and community level of the health systems.

The World Health Organization issues two new guidance documents to support implementation of next generation sequencing to detect drug-resistant TB.

A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.

Two new clinical trials find first-ever safe and effective treatment to prevent multidrug-resistant TB in both children and adults.

endTB clinical trial offers multiple new shortened drug regimens to treat adults and children with multidrug–resistant TB.

Results of LIFT-TB operational research on BPaL regimen for treating drug-resistant TB in Central and Southeast Asia.

The roadmap outlines an ambitious five-year plan with 10 key actions to improve the prevention, treatment, and care of TB in children and adolescents.